Abstract
Background
The contemporary causes of postoperative mortality in orthopedic surgery are not well characterized.
Objective
This study aimed to describe the epidemiology of postoperative complications among adult patients who underwent orthopedic surgery and inform their relationships with 30-day mortality.
Methods
Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) was a prospective cohort study involving 40,004 adult patients who underwent noncardiac surgery across 28 centers in 14 countries. For the subset of patients who underwent orthopedic surgery, a Cox proportional hazards model was used to determine time-dependent associations between various surgical complications and 30-day postoperative mortality. Analyses were adjusted for preoperative and surgical variables.
Results
Among 8385 patients who underwent an orthopedic surgery in VISION, 1.6% (n=132) died within 30 days of surgery. Of the 132 deaths, 63.6% (n=84) occurred in hospital during the index hospitalization, while 36.4% (n=48) occurred after discharge. The incidence of death across the subcategories of orthopedic surgery was above-knee amputation (30/221, 13.6%), internal fixation of femur (29/750, 3.9%), lower leg amputation (9/252, 3.6%), major hip or pelvic surgery (49/2898, 1.7%), major spine surgery (8/1405, 0.6%), and knee arthroplasty (7/2876, 0.2%). A total of 6 postoperative complications (myocardial injury after noncardiac surgery [MINS], major bleeding, infection without sepsis, sepsis, stroke, and atrial fibrillation) were associated with death in adjusted analyses. The greatest attributable fractions of postoperative mortality (ie, proportion of deaths in the cohort that can be attributed to each complication, if causality were established) were from MINS (1454/8385, 17.3%; hazard ratio [HR] 2.08, 95% CI 1.38‐3.14; P<.001; attributable fraction=20.6%), major bleeding (2422/8385, 28.9%; HR 1.95, 95% CI 1.34‐2.85; P<.001; attributable fraction=16.5%), and sepsis (318/8385, 3.8%; HR 6.24, 95% CI 3.85‐10.12; P<.001; attributable fraction=9.7%).
Conclusions
The complications most attributable to 30-day mortality following orthopedic surgery were MINS, major bleeding, and sepsis. These findings highlight areas for further study to mitigate perioperative mortality in orthopedic surgery. MINS demonstrated the highest attributable fraction for mortality (20.6%), emphasizing the importance of appropriate MINS screening, diagnosis, and management.
Introduction
Globally, the number of orthopedic surgeries performed annually is estimated to have approached 31.4 million procedures in 2024 [1]. Among these patients, the mortality rate is broadly estimated to be between 0.6% to 8.7%. Even at the lower end of this estimated range, mortality after orthopedic surgery represents a substantial health issue [2-5]. Much of the existing mortality data are derived from patients with hip fracture and orthopedic trauma, which represents only a small fraction of the entire orthopedic surgery population [2-5]. This highlights the need to better elucidate mortality rates in a broad sample of general contemporary patients who underwent orthopedic surgery.
The largest study to date in this area used the National Hospital Discharge Survey to identify risk factors for mortality in orthopedic surgery across a nationwide sample of hospitals in the United States [5]. However, this study is limited by the retrospective nature of the study, reliance on administrative data, and older data. Furthermore, the National Hospital Discharge Survey is considered less reliable in reflecting morbidity and complications [5-10]. Considering this, an updated and accurate understanding of modifiable risk factors for death in orthopedic surgery is needed.
Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) was a large prospective cohort study that included patients who underwent noncardiac surgery and were systematically followed to document postoperative complications, including mortality [11]. We previously reported the incidence of perioperative complications and associated mortality for the entire VISION study population. Patients undergoing orthopedic surgery represent a unique population that increasingly includes older adults with rising prevalence of cardiovascular disease [12-14]. This necessitates specialty-specific epidemiologic data.
The objective of this prospective cohort substudy was to describe the epidemiology of postoperative complications and death, evaluate the associations between these postoperative complications and death, and report the attributable fractions of each complication for death among a contemporary orthopedic surgery cohort.
Methods
Ethical Considerations
The research ethics board at each participating site approved the protocol before patient recruitment. This study was approved by the Hamilton Integrated Research Ethics Board under the project number 07-220. All participants provided informed consent and we followed the ethical standard principles of the Declaration of Helsinki, including maintaining privacy and confidentiality of research participants' data. No compensation was provided to participants.
Study Design
The design and methods of the VISION study have been previously described [11,15]. In summary, VISION was an international prospective cohort study, which enrolled 40,004 patients who underwent noncardiac surgery across 28 centers in 14 countries from August 2007 to November 2013. Patients aged ≥45 years, who underwent noncardiac surgery, receiving general or regional anesthesia, and requiring at least 1 overnight hospital stay after surgery were eligible for inclusion. This inclusion criteria was determined a priori with the intention to efficiently identify those who are at higher risk of mortality and capture a greater number of mortality outcomes and perioperative complications. Each participating hospital obtained approval from their research ethics board prior to the start of patient enrollment. Refer to Multimedia Appendix 1 for funding sources. The Strengthening the Reporting of Observational Studies in Epidemiology Statement was followed (Checklist 1).
Analysis Population
Patients who were enrolled in the VISION study and underwent an orthopedic procedure (including spine surgery) were included in this substudy. According to the VISION definitions, this would include surgeries categorized as major hip or pelvic surgery, internal fixation of femur, knee arthroplasty, above-knee amputation, lower leg amputation, and major spine surgery.
Follow-Up
Patients were followed for 30 days following their surgery and were censored at the time of their last assessment if the 30-day follow-up was not complete.
Complications Variables
Definitions for all variables included in the analyses are provided in (Multimedia Appendix 2). The primary outcome was time to all-cause mortality. The following postoperative complications during the first 30 days after surgery were investigated: myocardial injury after noncardiac surgery (MINS), venous thromboembolism (VTE), stroke, major bleeding, acute kidney injury (AKI) resulting in dialysis, sepsis, infection without sepsis, new clinically important atrial fibrillation, and congestive heart failure [11,12,16-19,undefined,undefined,undefined]. These variables were selected for clinical relevance while being parsimonious to preserve model stability. Of note, major bleeding was defined using a previously validated definition in the perioperative setting demonstrating independent association with 30-day mortality [18,19].
Statistical Analysis
A statistical analysis plan was written before undertaking analyses for this study, which was finalized in June 2023. Descriptive statistics were used to report patient characteristics, as well as the incidence of death and postoperative complications. As AKI resulting in dialysis occurred at the rate of 0.2%, this variable was omitted from the model to preserve model stability.
To determine the relationship between complications and 30-day mortality, we used a time-dependent Cox proportional hazards model and adjusted for baseline characteristics that were known to be independently associated with 30-day mortality, according to previous VISION analyses [11]. Complications were modeled as time-dependent covariates, allowing for multiple events per patient and accounting for their timing relative to death. This approach enabled assessment of the association between each complication with mortality rather than assignment of a single causal event. This model was adjusted for age category (65‐75 vs 45‐65 years, and age ≥75 vs 45‐65 years), cancer at the time of surgery, history of chronic obstructive pulmonary disease, surgery urgency (emergent: <24 hours from admission for an acute surgical condition, urgent: 24‐72 hours from admission for an acute surgical condition, nonemergent: all other surgeries), and history of peripheral arterial disease. All variables included in the model were selected a priori. We reported the adjusted hazard ratios (HRs) and corresponding 95% CIs. To avoid optimistic estimation of the c-statistic from possible overfitting, model performance was assessed using the c-statistic corrected for optimism using 1000 bootstrapped samples [20]. This involved the generation of 1000 simulated datasets through random sampling and replacement from the original dataset to estimate model performance while accounting for overfitting. Attributable fractions for death were calculated using an established method [21]. The attributable fraction represents the proportion of deaths that would not have occurred in the VISION orthopedic cohort if the complication had not occurred, if we assumed a causal relationship between the complication and death. Attributable fraction methods have been increasingly used in perioperative and epidemiologic research. Prior applications include large cohort analyses in noncardiac surgery and population health studies evaluating modifiable contributors to mortality [11,17,21-23,undefined,undefined]. There were 10 events per variable included in the model, which supports model stability [24].
For all tests, we used α <.05 as the level of significance. Analyses were performed using R statistical software (version 4.2.2; R Foundation for Statistical Computing) using the “survival,” “epiR,” and “ggplot2” packages.
Results
Patient Characteristics
Within the 40,004 patients enrolled in the overall VISION study, 21% (8385/40,004) underwent an orthopedic surgery and were included in these analyses. Figure 1 demonstrates the flow of patient inclusion. Table 1 presents the baseline characteristics of the participants. More than half of the patients were aged >64 years, and 57.3% (4802/8385) were female. There was no loss to follow-up in the orthopedic surgery population.
Figure 1. Flow of patient inclusion in the Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) orthopedic surgery substudy. Note: in the overall VISION study, 284 patients had 2 or 3 surgical categories.
Table 1. Baseline characteristics of the orthopedic surgery cohort.
| Characteristics | Participants, n (%) | Number of deaths within 30 days, n (%) |
|---|---|---|
| Age (years) | ||
| 45‐64 | 3411 (40.7) | 31 (0.9) |
| 65‐74 | 2418 (28.8) | 20 (0.8) |
| ≥75 | 2556 (30.5) | 81 (3.2) |
| Sex: female | 4802 (57.3) | 76 (1.6) |
| History of | ||
| Hypertension | 4948 (59) | 89 (1.8) |
| Diabetes | 1823 (21.8) | 44 (2.4) |
| Coronary artery disease | 1253 (15) | 41 (3.3) |
| Peripheral arterial disease | 519 (6.2) | 39 (7.5) |
| Chronic obstructive pulmonary disease | 640 (7.6) | 33 (5.2) |
| Coronary revascularization | 470 (5.6) | 6 (1.3) |
| Stroke | 398 (4.7) | 20 (5) |
| Congestive heart failure | 401 (4.8) | 20 (5) |
| Active cancer | 320 (3.8) | 13 (4.1) |
| Atrial fibrillation | 323 (3.9) | 11 (3.4) |
| Preoperative estimated glomerular filtration rate (mL/min/1.73 m2) | ||
| <30 | 294 (3.7) | 26 (8.8) |
| 30‐44 | 503 (6.2) | 22 (4.4) |
| 45‐59 | 988 (12.3) | 12 (1.2) |
| ≥60 | 6264 (77.8) | 67 (1.1) |
| Types of orthopedic surgery | ||
| Major hip or pelvic surgery | 2898 (34.6) | 49 (1.7) |
| Internal fixation of femur | 750 (8.9) | 29 (3.9) |
| Knee arthroplasty | 2876 (34.3) | 7 (0.2) |
| Above-knee amputation | 221 (2.6) | 30 (13.6) |
| Lower leg amputation | 252 (3) | 9 (3.6) |
| Major spine surgery | 1405 (16.8) | 8 (0.6) |
| Subcategory of surgery | ||
| Nonemergent | 7369 (87.9) | 81 (1.1) |
| Urgent or emergent | 1016 (12.1) | 51 (5) |
| Type of anesthesia | ||
| General only | 2436 (29.1) | 36 (1.5) |
| Neuraxial (spinal or epidural) only | 4182 (49.9) | 72 (1.7) |
| General with nitrous oxide only | 424 (5.1) | 10 (2.4) |
| General and thoracic epidural only | 10 (0.1) | 0 (0) |
| General and nerve block only | 424 (5.1) | 2 (0.5) |
| Other | 903 (10.8) | 12 (1.3) |
Among 8385 patients, 34.6% (n=2898) underwent a major hip or pelvic surgery, 34.3% (n=2876) underwent knee arthroplasty, 16.8% (n=1405) underwent a major spine surgery, 8.9% (n=750) underwent internal fixation of femur, 3% (n=252) underwent lower leg amputation, and 2.6% (n=221) underwent above-knee amputation. The majority of patients (n=7370, 87.9%) underwent nonemergent surgery.
Incidence of Death Within 30 Days After Surgery
There were 132 (1.6%) deaths in the orthopedic surgery cohort within 30 days after surgery (Table 2). Of the 132 deaths, 63.6% (84/132) occurred in hospital during the index hospitalization, while the remaining 36.4% (48/132) occurred after discharge. In 1.5% (2/132) of the deaths, patients died in the operating room. The median time to death was 13.5 (IQR 6‐21) days. Refer to Table 2 for incidence of death according to subcategories of orthopedic surgery. Death rates by nonemergent, urgent, and emergent surgeries were 1.1% (81/7288), 5.7% (46/812), and 3.3% (5/153), respectively. Risk of 30-day mortality was increased in emergent and urgent surgeries compared to nonemergent surgeries in adjusted analyses (HR 2.30, 95% CI 1.61‐3.42; P<.001).
Table 2. Thirty-day perioperative complications, overall and by subtypes of orthopedic surgerya.
| Outcome | Patients, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| All orthopedic surgery (N=8385) |
Subtypes of orthopedic surgery | ||||||
| Major hip or pelvic surgery (n=2898) |
Internal fixation of femur (n=750) |
Knee arthroplasty (n=2876) |
Above-knee amputation (n=221) |
Lower leg amputation (n=252) |
Major spine surgery (n=1405) |
||
| Major bleeding | 2422 (28.9) | 965 (33.3) | 287 (38.3) | 725 (25.2) | 103 (46.6) | 96 (38.1) | 258 (18.4) |
| MINSb | 1454 (17.3) | 563 (19.4) | 165 (22) | 347 (12.1) | 95 (43) | 95 (37.7) | 197 (14) |
| Sepsis | 318 (3.8) | 124 (4.3) | 33 (4.4) | 53 (1.8) | 30 (13.6) | 20 (7.9) | 60 (4.3) |
| Infection without sepsis | 562 (6.7) | 251 (8.7) | 63 (8.4) | 153 (5.3) | 14 (6.3) | 29 (11.5) | 54 (3.8) |
| Acute kidney injury with dialysis | 17 (0.2) | 4 (0.1) | 3 (0.4) | 2 (0.1) | 2 (0.9) | 3 (1.2) | 3 (0.2) |
| Stroke | 27 (0.3) | 9 (0.3) | 6 (0.8) | 6 (0.2) | 1 (0.5) | 2 (0.8) | 3 (0.2) |
| Venous thromboembolism | 123 (1.5) | 29 (1) | 16 (2.1) | 69 (2.4) | 1 (0.5) | 0 (0) | 8 (0.6) |
| Congestive heart failure | 124 (1.5) | 50 (1.7) | 29 (3.9) | 23 (0.8) | 13 (5.9) | 6 (2.4) | 4 (0.3) |
| New, clinically important atrial fibrillation | 93 (1.1) | 46 (1.6) | 13 (1.7) | 28 (1) | 2 (0.9) | 1 (0.4) | 4 (0.3) |
| Death | 132 (1.6) | 49 (1.7) | 29 (3.9) | 7 (0.2) | 30 (13.6) | 9 (3.6) | 8 (0.6) |
Subtypes of orthopedic surgery were not mutually exclusive (ie, 1 patient could have been categorized to have undergone more than 1 subtype of orthopedic surgery).
MINS: myocardial injury after noncardiac surgery.
Postoperative Complications and Relationship with 30-Day Mortality
The most common complication was major bleeding (2422/8385, 28.9% patients), followed by MINS (1454/8385, 17.3% patients), infection without sepsis (562/8385, 6.7% patients), sepsis (318/8385, 3.8% patients), then VTE (123/8385, 1.5% patients), congestive heart failure (124/8385, 1.5% patients), new atrial fibrillation (93/8385, 1.1% patients), stroke (27/8385, 0.3% patients), and AKI resulting in dialysis (17/8385, 0.2% patients). Refer to Table 2 for details. The median time from surgery to major bleeding was 2 (IQR 1‐3) days, MINS 2 (IQR 1‐3) days, infection without sepsis 10 (IQR 5‐17) days, and sepsis 8 (IQR 4‐13) days. Tables3 4 demonstrate the proportion of patients that underwent surgery for an acute fracture as well as the mortality rates according to the timing of surgery performed within each subcategory of orthopedic surgery.
Table 3. Surgery for acute fracture according to subcategories of orthopedic surgerya.
| Subcategory of orthopedic surgery | Surgery for acute fractureb, n (%) | |
|---|---|---|
| No (n=6767) | Yes (n=1616) | |
| Major hip or pelvic surgeryc | 1982 (29.3) | 916 (56.7) |
| Internal femoral fixation | 119 (1.8) | 622 (38.5) |
| Knee arthroplasty | 2854 (42.2) | 21 (1.3) |
| Above-knee amputation | 216 (3.2) | 3 (0.2) |
| Lower leg amputation | 243 (3.6) | 6 (0.4) |
| Major spine surgery | 1353 (20) | 48 (3) |
Surgery for acute fracture was considered nonelective surgery.
2 patients with missing subcategory of orthopedic surgery.
Surgery for hip and pelvis were not mutually exclusive.
Table 4. Mortality rates according to timing of surgery (emergent or urgent vs nonemergent surgery) within each subcategory of orthopedic surgery.
| Subcategory and timing of surgery | Proportionsa, n (%)b |
Mortality, n | Mortality ratec, % (95% CI) |
|---|---|---|---|
| Major hip or pelvic surgery (N=2898) | |||
| Emergent or urgent | 525 (18.1) | 22 | 4.2 (2.7‐6.4) |
| Nonemergent | 2373 (81.9) | 27 | 1.13 (0.8‐1.7) |
| Internal femoral fixation (N=741) | |||
| Emergent or urgent | 313 (42.2) | 14 | 4.5 (2.6‐7.6) |
| Nonemergent | 428 (57.8) | 15 | 3.5 (2.1‐5.8) |
| Knee arthroplasty (N=2875) | |||
| Emergent or urgent | 35 (1.2) | 0 | 0 |
| Nonemergent | 2840 (98.8) | 7 | 0.24 (0.1‐0.5) |
| Above-knee amputation (N=219) | |||
| Emergent or urgent | 48 (21.9) | 11 | 23 (12.5‐37.7) |
| Nonemergent | 171 (78.1) | 19 | 11.2 (7.0‐17.0) |
| Lower leg amputation (N=249) | |||
| Emergent or urgent | 49 (19.7) | 3 | 6 (1.6‐17.9) |
| Nonemergent | 200 (80.3) | 6 | 3.0 (1.2‐6.7) |
| Major spine surgery (N=1403) | |||
| Emergent or urgent | 46 (3.3) | 1 | 2 (0.1‐13.0) |
| Nonemergent | 1357 (96.7) | 7 | 0.51 (0.2‐1.1) |
| All (N=8385) | |||
| Emergent or urgent | 1016 (12.1) | 51 | 5.01 (3.8‐6.6) |
| Nonemergent | 7369 (87.9) | 81 | 1.09 (0.9‐1.4) |
2 patients with missing subcategory of orthopedic surgery
The proportion was calculated using the total number of patients within each surgical subcategory as the denominator.
The proportion is out of total patients receiving urgent or emergent surgery versus nonemergent, within each subcategory of surgery.
Postoperative complications associated with 30-day mortality included major bleeding (adjusted hazard ratio [aHR] 1.95, 95% CI 1.34‐2.85), MINS (aHR 2.08, 95% CI 1.38‐3.14), sepsis (aHR 6.24, 95% CI 3.85‐10.12), infection without sepsis (aHR 2.74, 95% CI 1.54‐4.85), stroke (aHR 6.01, 95% CI 2.19‐16.56), and new clinically important atrial fibrillation (aHR 2.65, 95% CI 1.25‐5.65). Refer to Table 5 for details. The c-statistic for model performance before and after correction for optimism was 0.87 and 0.85, respectively. Figure 2 is a cumulative hazard curve of the postoperative complications associated with 30-day mortality.
Table 5. Relation between perioperative complications and 30-day mortality in orthopedic surgery.
| Outcome | Patients who died, % (n) (95% CI) | Adjusted HRab (95% CI) | Attributable fraction (%) |
|---|---|---|---|
| Major bleeding (n=2422) | 3.1 (75) (2.44‐3.87) | 1.95 (1.34‐2.85) | 16.5 |
| No major bleeding (n=5960) | 0.9 (57) (0.73‐1.24) | Reference | N/Ac |
| MINSd (n=1454) | 4.3 (63) (3.35‐5.51) | 2.08 (1.38‐3.14) | 20.6 |
| No MINS (n=6931) | 0.9 (69) (0.78‐1.26) | Reference | N/A |
| Sepsis (n=318) | 9.4 (30) (6.46‐13.19) | 6.24 (3.85‐10.12) | 9.7 |
| Infection without sepsis (n=562) | 3 (17) (1.77‐4.80) | 2.74 (1.54‐4.85) | 3.8 |
| No sepsis or infection (n=7503) | 1.1 (85) (0.91‐1.40) | Reference | N/A |
| Acute kidney injury with dialysis (n=17) | 41.2 (7) (18.44‐67.07) | N/A | N/A |
| No acute kidney injury with dialysis (n=8366) | 1.5 (125) (1.25‐1.78) | N/A | N/A |
| Stroke (n=27) | 14.8 (4) (4.19‐33.73) | 6.01 (2.19‐16.56) | 1.5 |
| No stroke (n= 8356) | 1.5 (128) (1.28‐1.82) | Reference | N/A |
| Venous thromboembolism (n=123) | 2.4 (3) (0.51‐6.96) | 2.24 (0.70‐7.13) | N/A |
| No venous thromboembolism (n=8261) | 1.6 (129) (1.31‐1.85) | Reference | N/A |
| Congestive heart failure (n=124) | 15.3 (19) (9.48‐22.89) | 1.54 (0.81‐2.94) | N/A |
| No congestive heart failure (n=8259) | 1.4 (13) (1.13‐1.64) | Reference | N/A |
| New, clinically important atrial fibrillation (n=93) | 10.8 (10) (5.28‐18.89) | 2.65 (1.25‐5.65) | 2.2 |
| No new, clinically important atrial fibrillation (n=8290) | 1.5 (122) (1.22‐1.75) | Reference | N/A |
HR: hazard ratio.
Adjusted variables were as follows: age, history of peripheral vascular disease, history of chronic obstructive pulmonary disease, surgery urgency, and active cancer.
N/A: not applicable.
MINS: myocardial injury after noncardiac surgery.
Figure 2. Cumulative hazard curve of postoperative complications associated with 30-day mortality in orthopedic surgery. MINS: myocardial injury after noncardiac surgery.
Among the postoperative complications significantly associated with mortality, the greatest attributable fraction was for MINS (20.6%), followed by major bleeding (16.5%), then sepsis (9.7%), infection without sepsis (3.8%), new atrial fibrillation (2.2%), and stroke (1.5%).
Post hoc subgroup analyses performed according to surgery urgency demonstrated similar findings. Among those who underwent nonemergent surgeries, there were 81 deaths. Following adjustment, MINS (HR 2.02, 95% CI 1.22‐3.32), atrial fibrillation (HR 2.64, 95% CI 1.04‐6.89), major bleeding (HR 2.30, 95% CI 1.41‐3.76), sepsis (HR 6.27, 95% CI 3.43‐11.46), and stroke (HR 10.49, 95% CI 3.18‐34.63) were significantly associated with 30-day mortality. Among those who underwent urgent and emergent surgeries, there were 51 deaths. In this subgroup, with further reduced number of mortality events, infection without sepsis (HR 3.49, 95% CI 1.85‐6.24), MINS (HR 3.40, 95% CI 1.85‐6.24), and sepsis (HR 5.65, 95% CI 2.51‐12.70) were significantly associated with 30-day mortality.
Discussion
Principal Findings
This large international prospective cohort study involving 8385 patients who underwent orthopedic surgery demonstrated a 1.6% (132/8385) mortality rate. Major bleeding, MINS, infection without sepsis, sepsis, stroke, and new clinically important atrial fibrillation were significantly associated with 30-day mortality. Among these, the greatest attributable fraction for death in our cohort was from MINS (1454/8385, 21%), major bleeding (2422/8385, 17%), sepsis (318/8385, 10%), infection without sepsis (562/8385, 4%), stroke (27/8385, 2%), and new atrial fibrillation (93/8385, 2%).
Consistent with prior studies that reported 30-day mortality rates ranging from 0.6% to 8.7%, this work demonstrated a 1.6% (132/8385) mortality rate [2-4]. Our study also demonstrated substantial variations in mortality across subcategories of orthopedic surgery and surgery urgency. Traditional preoperative risk scoring systems do not consider the nuances between surgical procedures that contribute to notable variations in mortality risk [25]. We found substantial mortality differences across surgical procedures within orthopedic surgery, which urges greater consideration of procedure type for preoperative risk stratification and consideration of higher-level postoperative monitoring (eg, admission to intensive cardiac care unit and telemetry).
Among the few studies that investigate complications associated with mortality in orthopedic surgery, pneumonia, acute renal failure, stroke, myocardial infarction, and MINS have been reported [5,26]. Our results are unique in identifying major bleeding to be a risk factor for death in the orthopedic surgery cohort. Previous studies did not select postoperative bleeding as a potential variable to explore, despite 80% of 739 orthopedic surgeons and 50 anesthesiologists in an international survey responding that they were either concerned or very concerned for bleeding in orthopedic surgery populations [27]. Our results demonstrate that major bleeding in orthopedic surgery is common and is associated with mortality, necessitating further investigations in this area to improve patient outcomes.
Although a major bleeding event was the most common complication in our cohort, MINS demonstrated the greatest attributable fraction for death. In other words, although an overall smaller number of patients experienced MINS, a greater number of patients with MINS died within 30 days of surgery compared to the number of patients who experienced major bleeding. This is unique to the orthopedic surgery cohort compared to the overall VISION mortality analyses and general surgery mortality substudy, where major bleeding had the highest attributable fraction for death [11,17]. Certainly, the varying risk profiles, propensity for bleeding, and cardiovascular stress by surgical subspecialties contribute to the differences in these results. This emphasizes the need for specialty-specific data to inform surgery-specific practice.
Another potential explanation is the unique practice of bleeding prophylaxis that is commonplace in orthopedic surgery [28-31]. Consistent demonstration of perioperative bleeding reduction with tranexamic acid use in orthopedic surgery–specific research has led to the routine use of prophylactic tranexamic acid in orthopedic surgery for many years, particularly in trauma, joint, and spine surgery [28-33]. This is not commonplace in other noncardiac surgical specialties, despite recent evidence to support its safety and efficacy in these contexts [28-30,34-37,undefined,undefined,undefined,undefined,undefined]. The long-standing practice of routine prophylaxis for perioperative bleeding in orthopedic surgery may have contributed to reduced bleeding severity and lower attributable fraction for death in this cohort compared to the overall and general surgery cohorts. If this were to be true, it is also worth noting that the rate of VTE in this orthopedic cohort was only around 1% (123/8385), which is similar to the incidence found in the noncardiac and general surgery cohorts [11].
Of the postoperative complications investigated, MINS was the second most common complication occurring in 17.3% (1454/8385) of the orthopedic surgery cohort. We also demonstrated a 12% (347/2876) incidence of MINS in the knee arthroplasty subcategory. Previously reported rates of myocardial infarction (MI) after knee arthroplasty have ranged between 0.3% and 2.2% [38,39]. Considering MINS encompasses a broader spectrum of myocardial injury than MI, the larger incidence of MINS was expected, especially as high-sensitivity troponin assays were used for monitoring. Among the few existing studies investigating the incidence of MINS, the results have varied significantly, likely due to limitations in very small sample sizes (ie, 1/82, 1.2% incidence vs 68/160, 42% incidence) [40,41]. Our study included 2876 patients who underwent knee arthroplasty, representing the largest cohort in which the epidemiology of MINS has been studied. As MINS is largely asymptomatic, these findings highlight the importance of identifying MINS for postoperative risk stratification and downstream management, as emerging evidence suggests targeted treatment may reduce future cardiovascular events [12,16,25,42].
Finally, subgroup analyses by surgery urgency demonstrated minor differences in postoperative complications that were found to be associated with mortality between the emergent and nonemergent groups. Specifically, major bleeding was not associated with mortality in the urgent-emergent subgroup. Clinical interpretation of these findings is limited as these are post hoc analyses with reduced events per variable and therefore, model instability. However, these findings suggest differences in mortality determinants highlighting tailored strategies to address perioperative risks according to surgery urgency.
Limitations
There are a few limitations to consider. Only patients aged ≥45 years were included; thus, these findings may not apply to younger patients. Baseline variables (ie, age and estimated glomerular filtration rate) were modeled as a categorical variable to align with prior VISION analyses, although this approach may not fully capture potential nonlinear relationships. Additionally, as our inclusion criteria were targeted to include a higher risk surgical population, the present results would not apply for patients undergoing low-risk, same-day surgeries. The granularity of the data are limited to the subcategories of orthopedic surgery that were predefined before the start of the study [43-45]. Although orthopedic procedures are heterogeneous, combining them enabled sufficient power to evaluate associations between relatively infrequent complications and mortality. We report subtype-specific complication rates (Table 2), demonstrating that major bleeding, MINS, and sepsis were consistently among the most common complications across procedures. While procedure-specific attributable fractions were not feasible due to limited events, our findings identify broadly relevant targets for perioperative risk reduction. The stability of a Cox regression model is dependent on the events per variable. The base model meets the lower acceptable cutoff at 10 events per variable, suggesting adequate power for the primary analysis; there remains potential risk for overfitting [24,46]. However, the negligible change in the c-statistic after correcting for optimism suggests overfitting may not be a significant issue [20]. Variation in VTE prophylaxis practices, which were not captured in detail in this study, may contribute to differences in bleeding risk and represents a potential unmeasured confounder. Finally, complications such as infection and sepsis may occur later in the postoperative course, potentially reducing their relative contribution in time-dependent analyses within a 30-day follow-up period, particularly given their lower event frequency compared to earlier complications such as bleeding or MINS.
To our knowledge, this is the first large prospective study exploring the association of various postoperative complications and death in a global prospective orthopedic surgery study. The inclusion of diverse participants across 14 countries increases the generalizability of our results. Furthermore, with no loss to follow-up and the collection of time-dependent data, we were able to increase precision and reduce bias in fulfilling our objectives by creating a realistic model that accounts for the changes in risk factors for survival that occur over time.
Conclusions
This large international prospective cohort study of patients undergoing orthopedic surgery (7369/8385, 88% nonemergent) demonstrated a 30-day mortality rate of 1.6% (132/8385). Adjusted analyses demonstrated major bleeding, MINS, sepsis, infection without sepsis, stroke, and atrial fibrillation to be associated with mortality. The highest attributable fraction of death in our cohort was contributed by MINS, major bleeding, sepsis, and infection without sepsis, which highlights areas for further study to reduce mortality among patients who underwent orthopedic surgery.
Supplementary material
Acknowledgments
Abbreviations
- aHR
adjusted hazard ratio
- AKI
acute kidney injury
- HR
hazard ratio
- MI
myocardial infarction
- MINS
myocardial injury after noncardiac surgery
- VISION
Vascular Events in Noncardiac Surgery Patients Cohort Evaluation
- VTE
venous thromboembolism
Footnotes
Funding: Please see Multimedia Appendix 1 for funding sources.
Data Availability: The datasets generated or analyzed during this study are not publicly available due but are available from the corresponding author on reasonable request.
Conflicts of Interest: On the basis of study questions PJD has originated and grants he has written, he has received grants from Abbott Diagnostics, AOP Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, CloudDX, Covidien, Octapharma, Philips Healthcare, Roche Diagnostics, Siemens, and Stryker. PJD has participated in advisory board meetings for GlaxoSmithKline, Boehringer Ingelheim, Bayer, and Quidel Canada. He attended expert panel meetings with AstraZeneca and Boehringer Ingelheim; served as a consultant for a call with Roche Pharma; and conducted consultancy work for Abbott, AstraZeneca, Renibus Therapeutics, Roche Canada, and Trimedic. He has also been invited as a speaker with Bayer Inc, Novartis Pharma Canada, and Abbott Diagnostics. FKB holds a PHRI Career Award and a McMaster University Department of HEI Mid-Career Research Award. She received investigator-initiated research grants from Roche Diagnostics and SIEMENS, and attended advisory board meetings from Abbott. ED received investigator-initiated research grants from Roche Laboratories and Abbott Laboratories, outside of the submitted work. She receives a clinician-researcher salary award from the Fonds de recherche du Québec-Santé. DC received consulting fees from Roche Diagnostics and Trimedics. PES has received consulting fees from Incyte Biosciences Canada and Hoffman La Roche. ORA reports a relationship with Stryker Canada that includes speaking and lecture fees. He is the tier 2 Canada Research Chair in Joint Preservation and President/Owner of Notch Academy. MKW is supported by the CANTRAIN Clinical Trials Training Platforms – Doctoral Studentship Award. DT has received funding from Stryker Canada.
References
- 1.Kamel I, Ahmed MF, Sethi A. Regional anesthesia for orthopedic procedures: what orthopedic surgeons need to know. World J Orthop. 2022 Jan 18;13(1):11–35. doi: 10.5312/wjo.v13.i1.11. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Banerjee S, Suresh G, Kale AB, Sathe AH. An audit of admissions and mortality of orthopedic indoor patients in a tertiary care hospital of India. J Clin Orthop Trauma. 2020 Jul;11(Suppl 4):S518–S521. doi: 10.1016/j.jcot.2020.04.012. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sheikh HQ, Hossain FS, Aqil A, Akinbamijo B, Mushtaq V, Kapoor H. A comprehensive analysis of the causes and predictors of 30-day mortality following hip fracture surgery. Clin Orthop Surg. 2017 Mar;9(1):10–18. doi: 10.4055/cios.2017.9.1.10. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tan HB, MacDonald DA, Matthews SJ, Giannoudis PV. Incidence and causes of mortality following acute orthopaedic and trauma admissions. Ann R Coll Surg Engl. 2004 May;86(3):156–160. doi: 10.1308/003588404323043256. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am. 2002 Apr;84(4):562–572. doi: 10.2106/00004623-200204000-00009. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 6.Ramirez LF, Thisted R. Using a national health care data base to determine surgical complications in community hospitals: lumbar discectomy as an example. Neurosurgery. 1989 Aug;25(2):218–225. doi: 10.1097/00006123-198908000-00011. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 7.Ciol MA, Deyo RA, Howell E, Kreif S. An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations. J Am Geriatr Soc. 1996 Mar;44(3):285–290. doi: 10.1111/j.1532-5415.1996.tb00915.x. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 8.Derkay CS. Pediatric otolaryngology procedures in the United States: 1977-1987. Int J Pediatr Otorhinolaryngol. 1993 Jan;25(1-3):1–12. doi: 10.1016/0165-5876(93)90004-m. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 9.Gillum RF. Peripheral arterial occlusive disease of the extremities in the United States: hospitalization and mortality. Am Heart J. 1990 Dec;120(6 Pt 1):1414–1418. doi: 10.1016/0002-8703(90)90257-x. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 10.Owings MF, Kozak LJ. Ambulatory and inpatient procedures in the United States, 1996. [25-05-2025];Vital Health Stat 13. 1998 Nov;13(139):1–119. https://pubmed.ncbi.nlm.nih.gov/9866429/ URL. Accessed. Medline. [PubMed] [Google Scholar]
- 11.Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Spence J, LeManach Y, et al. Association between complications and death within 30 days after noncardiac surgery. CMAJ. 2019 Jul 29;191(30):E830–E837. doi: 10.1503/cmaj.190221. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Thomas S, Borges F, Bhandari M, et al. Association between myocardial injury and cardiovascular outcomes of orthopaedic surgery: a vascular events in noncardiac surgery patients cohort evaluation (VISION) substudy. J Bone Joint Surg Am. 2020 May 20;102(10):880–888. doi: 10.2106/JBJS.18.01305. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 13.Salerno SM, Carlson DW, Soh EK, Lettieri CJ. Impact of perioperative cardiac assessment guidelines on management of orthopedic surgery patients. Am J Med. 2007 Feb;120(2):185. doi: 10.1016/j.amjmed.2005.11.009. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 14.Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ. 2005 Sep 13;173(6):627–634. doi: 10.1503/cmaj.050011. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Devereaux PJ, Chan MT, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012 Jun 6;307(21):2295–2304. doi: 10.1001/jama.2012.5502. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 16.Writing Committee for the VISION Study Investigators. Devereaux PJ, Biccard BM, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017 Apr 25;317(16):1642–1651. doi: 10.1001/jama.2017.4360. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 17.Park LJ, Borges FK, Ofori S, et al. Association between complications and death within 30 days after general surgery: a vascular event in noncardiac surgery patients cohort evaluation (VISION) substudy. Ann Surg. 2025 Dec 1;282(6):1007–1013. doi: 10.1097/SLA.0000000000006372. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 18.Roshanov PS, Eikelboom JW, Crowther M, et al. Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. CMAJ Open. 2017 Aug 4;5(3):E594–E603. doi: 10.9778/cmajo.20160106. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Roshanov PS, Eikelboom JW, Sessler DI, et al. Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. Br J Anaesth. 2021 Jan;126(1):163–171. doi: 10.1016/j.bja.2020.06.051. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 20.Smith GC, Seaman SR, Wood AM, Royston P, White IR. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014 Aug 1;180(3):318–324. doi: 10.1093/aje/kwu140. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Rückinger S, von Kries R, Toschke AM. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors. BMC Med Res Methodol. 2009 Jan 23;9(1):7. doi: 10.1186/1471-2288-9-7. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.von Cube M, Timsit JF, Schumacher M, Motschall E, Schumacher M. Quantification and interpretation of attributable mortality in core clinical infectious disease journals. Lancet Infect Dis. 2020 Dec;20(12):e299–e306. doi: 10.1016/S1473-3099(20)30485-0. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 23.Mansournia MA, Altman DG. Population attributable fraction. BMJ. 2018 Feb 22;360:k757. doi: 10.1136/bmj.k757. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 24.Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710–718. doi: 10.1093/aje/kwk052. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 25.Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017 Jan;33(1):17–32. doi: 10.1016/j.cjca.2016.09.008. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 26.Hu W, Chen Y, Zhao K, et al. Association of perioperative myocardial injury with 30-day and long-term mortality in older adult patients undergoing orthopedic surgery in China. Med Sci Monit. 2021 Dec 25;27:e932036. doi: 10.12659/MSM.932036. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ginzburg E, Dujardin F. Physicians’ perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey. J Thromb Thrombolysis. 2011 Feb;31(2):188–195. doi: 10.1007/s11239-010-0498-9. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 28.Wong J, George RB, Hanley CM, Saliba C, Yee DA, Jerath A. Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. Can J Anesth. 2021 Jun;68(6):894–917. doi: 10.1007/s12630-021-01967-7. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 29.Jennings JD, Solarz MK, Haydel C. Application of tranexamic acid in trauma and orthopedic surgery. Orthop Clin North Am. 2016 Jan;47(1):137–143. doi: 10.1016/j.ocl.2015.08.014. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 30.Lin ZX, Woolf SK. Safety, efficacy, and cost-effectiveness of tranexamic acid in orthopedic surgery. Orthopedics. 2016;39(2):119–130. doi: 10.3928/01477447-20160301-05. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 31.Colomina MJ, Contreras L, Guilabert P, Koo M, M Ndez E, Sabate A. Clinical use of tranexamic acid: evidences and controversies. Braz J Anesthesiol. 2022;72(6):795–812. doi: 10.1016/j.bjane.2021.08.022. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013 May 7;6:184. doi: 10.1186/1756-0500-6-184. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Goldstein K, Jones C, Kay J, Shin J, de Sa D. Tranexamic acid administration in arthroscopic surgery is a safe adjunct to decrease postoperative pain and swelling: a systematic review and meta-analysis. Arthroscopy. 2022 Apr;38(4):1366–1377. doi: 10.1016/j.arthro.2021.10.001. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 34.Montroy J, Hutton B, Fergusson DA, et al. Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre. Curr Oncol. 2020 Dec;27(6):e560–e568. doi: 10.3747/co.27.6613. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022 May 26;386(21):1986–1997. doi: 10.1056/NEJMoa2201171. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 36.Tsan SE, Viknaswaran NL, Cheong CC, et al. Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. Anaesthesia. 2023 Sep;78(9):1153–1161. doi: 10.1111/anae.16058. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 37.Houston BL, Fergusson DA, Falk J, et al. Prophylactic tranexamic acid use in non-cardiac surgeries at high risk for transfusion. Transfus Med. 2021 Aug;31(4):236–242. doi: 10.1111/tme.12780. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 38.Lu N, Misra D, Neogi T, Choi HK, Zhang Y. Total joint arthroplasty and the risk of myocardial infarction: a general population, propensity score–matched cohort study. Arthritis Rheumatol. 2015 Oct;67(10):2771–2779. doi: 10.1002/art.39246. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Petersen PB, Kehlet H, Jørgensen CC, Lundbeck Foundation Center for Fast-track Hip and Knee Replacement Collaborative Group Myocardial infarction following fast-track total hip and knee arthroplasty-incidence, time course, and risk factors: a prospective cohort study of 24,862 procedures. Acta Orthop. 2018 Dec;89(6):603–609. doi: 10.1080/17453674.2018.1517487. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Van Zyl RD, Burger MC, Jordaan JD. Prevalence of a postoperative troponin leak in patients with cardiac risk factors undergoing knee and hip arthroplasty in a South African population. S Afr Med J. 2020 Mar 30;110(4):320–326. doi: 10.7196/SAMJ.2020.v110i4.14133. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 41.Lee S, Allen AJ, Morley E, et al. Perioperative myocardial injury risk after elective knee and hip arthroplasty in patients with a high risk of obstructive sleep apnea. Sleep Breath. 2021 Mar;25(1):513–515. doi: 10.1007/s11325-020-02068-3. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 42.Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018 Jun 9;391(10137):2325–2334. doi: 10.1016/S0140-6736(18)30832-8. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 43.Thakker A, Briggs N, Maeda A, Byrne J, Davey JR, Jackson TD. Reducing the rate of post-surgical urinary tract infections in orthopedic patients. BMJ Open Qual. 2018;7(2):e000177. doi: 10.1136/bmjoq-2017-000177. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Al-Mulhim FA, Baragbah MA, Sadat-Ali M, Alomran AS, Azam MQ. Prevalence of surgical site infection in orthopedic surgery: a 5-year analysis. Int Surg. 2014;99(3):264–268. doi: 10.9738/INTSURG-D-13-00251.1. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA. 2023 Jan 17;329(3):244–252. doi: 10.1001/jama.2022.24075. doi. Medline. [DOI] [PubMed] [Google Scholar]
- 46.Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol. 2016 Aug;76:175–182. doi: 10.1016/j.jclinepi.2016.02.031. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.